John Overdeck’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

John Overdeck’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-102	Closed	-$7.73K	–	3421
2024 Q1	$7.73K	Sell	102 -95	-48%	-$12.5K	﹤0.01%	2962
2023 Q4	$35.1K	Buy	+197	New	+$96.9K	﹤0.01%	3023
2022 Q4	–	Sell	-19	Closed	-$76K	–	3132
2022 Q3	$76K	Sell	19 -109	-85%	-$429K	﹤0.01%	2267
2022 Q2	$333K	Sell	128 -134	-51%	-$349K	﹤0.01%	1988
2022 Q1	$844K	Sell	262 -64	-20%	-$275K	﹤0.01%	1786
2021 Q4	$2.04M	Buy	326 +71	+28%	+$545K	﹤0.01%	1904
2021 Q3	$2.36M	Sell	255 -215	-46%	-$1.85M	0.01%	1833
2021 Q2	$4.76M	Buy	+470	New	+$7.72M	0.01%	1238

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CHA

Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

John Overdeck's SEEL Position: Q2 2024 in Review

John Overdeck sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2024, closing a stake of 102 shares — an estimated $7.73K sold.

John Overdeck first reported a position in SEEL in Q2 2021 and held it in 8 quarters. The position peaked at $4.76M in Q2 2021. 18 funds tracked by Wall St. Rank hold SEEL as of Q2 2024.

John Overdeck reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
John Overdeck sold 102 Seelos Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $7.73K.
John Overdeck first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
John Overdeck's Seelos Therapeutics, Inc. Common Stock position peaked at $4.76M in Q2 2021.
18 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.